Abbott to pay $385 million in baby formula case
Whistleblowers who exposed plant conditions to receive $69 million
Abbott Laboratories has agreed to pay approximately $385 million to resolve federal and state claims over manufacturing practices involving powdered infant formula and nutritional products, closing a major civil case stemming from the company's 2022 formula recall and shutdown of its plant in Sturgis, Michigan. The settlement does not constitute an admission of wrongdoing or a finding of liability.
The case originated with a qui tam whistleblower lawsuit filed under the False Claims Act by three former Abbott employees — Scott Millard, Kristine Cooper and Loren Cooper. The three whistleblowers will collectively receive approximately $69 million as their share of the federal government's recovery. The Justice Department alleged Abbott manufactured products between January 1, 2018, and December 31, 2022, at facilities in Sturgis, Michigan, and Casa Grande, Arizona, without complying with federal and state requirements.
The government's complaint described alleged problems with water control, equipment maintenance and contamination safeguards at the Sturgis facility. In one particularly striking allegation, plant personnel used umbrellas hung over manufacturing equipment to divert leaking water rather than permanently repairing the source of the leaks. Prosecutors also alleged Abbott failed to adequately identify, investigate and prevent potential contamination and, in some instances, did not disclose contamination test results requested by the FDA.
Under the settlement, Abbott will pay $348.7 million to the federal government and approximately $36.3 million to participating states to resolve claims involving programs including Medicaid and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). More than half of infant formula purchased in the United States is paid for with federal funds through WIC, according to the Justice Department.
The Sturgis plant was temporarily closed in February 2022 during an FDA investigation, and Abbott recalled powdered formula including products sold under its Similac brand. The shutdown contributed to a nationwide formula shortage. Abbott maintains that no unopened, distributed Abbott infant formula tested positive for Cronobacter sakazakii and notes that the CDC found no definitive link between the Sturgis facility and the clinical cases investigated.